FMP

FMP

Enter

PACB - Pacific Biosciences ...

photo-url-https://images.financialmodelingprep.com/symbol/PACB.png

Pacific Biosciences of California, Inc.

PACB

NASDAQ

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

1.36 USD

-0.02 (-1.47%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

78.89M

130.51M

128.3M

200.52M

154.01M

191.3M

237.61M

295.12M

366.57M

455.3M

Revenue %

-

65.43

-1.69

56.29

-23.19

24.21

24.21

24.21

24.21

Ebitda

38.97M

-250.76M

-282.24M

-277.28M

-356.38M

-134.14M

-166.61M

-206.94M

-257.04M

-319.26M

Ebitda %

49.4

-192.13

-219.98

-138.28

-231.4

-70.12

-70.12

-70.12

-70.12

Ebit

29.67M

-262.34M

-299.56M

-303.82M

-409.73M

-138.65M

-172.21M

-213.9M

-265.68M

-330M

Ebit %

37.61

-201.01

-233.48

-151.51

-266.04

-72.48

-72.48

-72.48

-72.48

Depreciation

9.3M

11.59M

17.32M

26.53M

53.35M

31.39M

38.99M

48.42M

60.15M

74.71M

Depreciation %

11.79

8.88

13.5

13.23

34.64

16.41

16.41

16.41

16.41

EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep